Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Davidson

Showing results (321-330 of 358) with videos related to

Pageof 36
Sort By:
Circulation|August 24, 2005
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart StudyLyle G Best, Ying Zhang, Elisa T Lee, et al.
Cancers|May 30, 2019
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric AdenocarcinomaMichael Davidson, Louise J Barber, Andrew Woolston, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Frontiers in Medicine|November 18, 2021
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource ImplicationsSumeet Hindocha, Des Campbell, Merina Ahmed, et al.
Schizophrenia (Heidelberg, Germany)|March 1, 2026
Persistent negative symptoms in the EULAST cohort: impact on functional outcomeLuigi Giuliani, Pasquale Pezzella, Giulia M Giordano, et al.
Lancet (London, England)|May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialAshish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
The Annals of Thoracic Surgery|January 28, 2010
Surgical revision after percutaneous mitral repair with the MitraClip deviceMichael Argenziano, Eric Skipper, David Heimansohn, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.
Pageof 36

Showing results (321-330 of 358) with videos related to

Sort By:
Pageof 36
Circulation|August 24, 2005
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart StudyLyle G Best, Ying Zhang, Elisa T Lee, et al.
Cancers|May 30, 2019
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric AdenocarcinomaMichael Davidson, Louise J Barber, Andrew Woolston, et al.
Gut|August 24, 2017
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancerIrene Yushing Chong, Lauren Aronson, Hanna Bryant, et al.
American Heart Journal|September 29, 2009
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibChristopher P Cannon, Hayes M Dansky, Michael Davidson, et al.
Frontiers in Medicine|November 18, 2021
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource ImplicationsSumeet Hindocha, Des Campbell, Merina Ahmed, et al.
Schizophrenia (Heidelberg, Germany)|March 1, 2026
Persistent negative symptoms in the EULAST cohort: impact on functional outcomeLuigi Giuliani, Pasquale Pezzella, Giulia M Giordano, et al.
Lancet (London, England)|May 10, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialAshish Sarraju, Danielle Brennan, Kierstyn Hayden, et al.
The Annals of Thoracic Surgery|January 28, 2010
Surgical revision after percutaneous mitral repair with the MitraClip deviceMichael Argenziano, Eric Skipper, David Heimansohn, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.
Pageof 36